Litigation
Celgene Corporation v. Mylan Pharmaceuticals Inc.
affirmed21-1154
- Terminated
- 2021-11-05
Patents at issue (3)
Plaintiffs (1)
Defendants (1)
Summary
Federal Circuit appeal of the 2:19-cv-05802 venue dismissal; affirmed on Nov. 5, 2021, holding Mylan lacked a regular and established place of business in New Jersey and that the ANDA submission, not the paragraph IV notice letter, is the operative infringing act.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).